Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications (review)

Biomedical Reports

Volumn 4, Issue 5, 2016, Pages 528-534

  Guo, Zhengrong ^a,b   Peng, Huanyan ^a,c   Kang, Jiwen ^a   Sun, Dianxing ^a  

^a BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^b FIRST HOSPITAL OF SHIJIAZHUANG   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cell penetrating peptides; Internalization; Peptide therapeutic; Protein transduction domain

Indexed keywords

ANTIINFLAMMATORY AGENT; BLEOMYCIN; CELL PENETRATING PEPTIDE; CLATHRIN; DIAGNOSTIC AGENT; DOXORUBICIN; FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; NUCLEOTIDE; PACLITAXEL; PEPTIDES AND PROTEINS; PLASMID DNA; QUANTUM DOT; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER THERAPY; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELL PENETRATION; CELL PHAGOCYTOSIS; CYTOTOXICITY; DNA TRANSFECTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; ESCHERICHIA COLI; GENE EXPRESSION; GENE SILENCING; HUMAN; IMAGING; INFLAMMATORY DISEASE; MEMBRANE BIOLOGY; MEMBRANE STRUCTURE; NEOPLASM; NONHUMAN; PINOCYTOSIS; PLURIPOTENT STEM CELL; PROTON TRANSPORT; REVIEW; TRANSITORY MEMBRANE STRUCTURE; VIRAL GENE DELIVERY SYSTEM;

EID: 85010912964     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2016.639     Document Type: Review

References (93)

1. Lindgren M, Hallbrink M, Prochiantz A and Langel U: Cell-penetrating peptides. Trends Pharmacol Sci 21: 99-103, 2000.
2. Green M and Loewenstein PM: Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55: 1179-1188, 1988.
3. Frankel AD and Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193, 1988.
4. Joliot A, Pernelle C, Deagostini-Bazin H and Prochiantz A: Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 88: 1864-1868, 1991.
5. Elliott G and O'Hare P: Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88: 223-233, 1997.
6. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B and Barsoum J: Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91: 664-668, 1994.
7. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT and Weissleder R: Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18: 410-414, 2000.
8. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P and Manjunath N: Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43, 2007.
9. Jafari S, Maleki Dizaj S and Adibkia K: Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery. Bioimpacts 5: 103-111, 2015.
10. Milletti F: Cell-penetrating peptides: Classes, origin, and current landscape. Drug Discov Today 17: 850-860, 2012.
11. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L and Rothbard JB: The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc Natl Acad Sci USA 97: 13003-13008, 2000.
12. Mai JC, Shen H, Watkins SC, Cheng T and Robbins PD: Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J Biol Chem 277: 30208-30218, 2002.
13. Tunnemann G, Ter-Avetisyan G, Martin RM, Stockl M, Herrmann A and Cardoso MC: Live-cell analysis of cell penetration ability and toxicity of oligo-arginines. J Pept Sci 14: 469-476, 2008.
14. Zahid M and Robbins PD: Cell-type specific penetrating peptides: Therapeutic promises and challenges. Molecules 20: 13055-13070, 2015.
15. Ragin AD, Morgan RA and Chmielewski J: Cellular import mediated by nuclear localization signal Peptide sequences. Chem Biol 9: 943-948, 2002.
16. Oehlke J, Scheller A, Wiesner B, Krause E, Beyermann M, Klauschenz E, Melzig M and Bienert M: Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta 1414: 127-139, 1998.
17. Deshayes S, Plénat T, Aldrian-Herrada G, Divita G, Le Grimellec C and Heitz F: Primary amphipathic cell-penetrating peptides: Structural requirements and interactions with model membranes. Biochemistry 43: 7698-7706, 2004.
18. Nan YH, Park IS, Hahm KS and Shin SY: Antimicrobial activity, bactericidal mechanism and LPS-neutralizing activity of the cell-penetrating peptide pVEC and its analogs. J Pept Sci 17: 812-817, 2011.
19. Johansson HJ, El-Andaloussi S, Holm T, Mäe M, Jänes J, Maimets T and Langel U: Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Mol Ther 16: 115-123, 2008.
20. Magzoub M, Sandgren S, Lundberg P, Oglecka K, Lilja J, Wittrup A, Göran Eriksson LE, Langel U, Belting M and Gräslund A: N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochem Biophys Res Commun 348: 379-385, 2006.
21. Eguchi A and Dowdy SF: siRNA delivery using peptide transduction domains. Trends Pharmacol Sci 30: 341-345, 2009.
22. Oehlke J, Krause E, Wiesner B, Beyermann M and Bienert M: Extensive cellular uptake into endothelial cells of an amphipathic beta-sheet forming peptide. FEBS Lett 415: 196-199, 1997.
23. Pujals S and Giralt E: Proline-rich, amphipathic cell-penetrating peptides. Adv Drug Deliv Rev 60: 473-484, 2008.
24. Pooga M, Hällbrink M, Zorko M and Langel U: Cell penetration by transportan. FASEB J 12: 67-77, 1998.
25. Schafmeister CE, Po J and Verdine GL: An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J Am Chem Soc 122: 5891-5892, 2000.
26. Ochocki JD, Mullen DG, Wattenberg EV and Distefano MD: Evaluation of a cell penetrating prenylated peptide lacking an intrinsic fluorophore via in situ click reaction. Bioorg Med Chem Lett 21: 4998-5001, 2011.
27. Covic L, Gresser AL, Talavera J, Swift S and Kuliopulos A: Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA 99: 643-648, 2002.
28. Gao S, Simon MJ, Hue CD, Morrison B III and Banta S: An unusual cell penetrating peptide identified using a plasmid display-based functional selection platform. ACS Chem Biol 6: 484-491, 2011.
29. Gao C, Mao S, Ditzel HJ, Farnaes L, Wirsching P, Lerner RA and Janda KD: A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. Bioorg Med Chem 10: 4057-4065, 2002.
30. Nakayama F, Yasuda T, Umeda S, Asada M, Imamura T, Meineke V and Akashi M: Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain: Involvement of internalization in the in vivo role of exogenous FGF12. J Biol Chem 286: 25823-25834, 2011.
31. Fonseca SB, Pereira MP and Kelley SO: Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 61: 953-964, 2009.
32. Madani F, Lindberg S, Langel U, Futaki S and Graslund A: Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys 2011: 414729, 2011.
33. Choi YS and David AE: Cell penetrating peptides and the mechanisms for intracellular entry. Curr Pharm Biotechnol 15: 192-199, 2014.
34. Wu X and Gehring W: Cellular uptake of the Antennapedia homeodomain polypeptide by macropinocytosis. Biochem Biophys Res Commun 443: 1136-1140, 2014.
35. Polanco C, Samaniego JL, Castañón-González JA, Buhse T and Sordo ML: Characterization of a possible uptake mechanism of selective antibacterial peptides. Acta Biochim Pol 60: 629-633, 2013.
36. Vivès E, Brodin P and Lebleu B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010-16017, 1997.
37. Derossi D, Joliot AH, Chassaing G and Prochiantz A: The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10450, 1994.
38. Veach RA, Liu D, Yao S, Chen Y, Liu XY, Downs S and Hawiger J: Receptor/transporter-independent targeting of functional peptides across the plasma membrane. J Biol Chem 279: 11425-11431, 2004.
39. Herce HD and Garcia AE: Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci USA 104: 20805-20810, 2007.
40. Pouny Y, Rapaport D, Mor A, Nicolas P and Shai Y: Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry 31: 12416-12423, 1992.
41. Lee MT, Hung WC, Chen FY and Huang HW: Many-body effect of antimicrobial peptides: On the correlation between lipid's spontaneous curvature and pore formation. Biophys J 89: 4006-4016, 2005.
42. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV and Lebleu B: Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278: 585-590, 2003.
43. Vivès E, Schmidt J and Pèlegrin A: Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786: 126-138, 2008.
44. Jones AT: Macropinocytosis: Searching for an endocytic identity and role in the uptake of cell penetrating peptides. J Cell Mol Med 11: 670-684, 2007.
45. Mayor S, Parton RG and Donaldson JG: Clathrin-independent pathways of endocytosis. Cold Spring Harb Perspect Biol 6: 6, 2014.
46. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G and Prochiantz A: Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 271: 18188-18193, 1996.
47. Kawamoto S, Takasu M, Miyakawa T, Morikawa R, Oda T, Futaki S and Nagao H: Inverted micelle formation of cell-penetrating peptide studied by coarse-grained simulation: Importance of attractive force between cell-penetrating peptides and lipid head group. J Chem Phys 134: 95103, 2011.
48. Tünnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F and Cardoso MC: Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J 20: 1775-1784, 2006.
49. Lundberg P, El-Andaloussi S, Sütlü T, Johansson H and Langel U: Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 21: 2664-2671, 2007.
50. Jones AT and Sayers EJ: Cell entry of cell penetrating peptides: tales of tails wagging dogs. J Control Release 161: 582-591, 2012.
51. Mueller J, Kretzschmar I, Volkmer R and Boisguerin P: Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjug Chem 19: 2363-2374, 2008.
52. Pysz MA, Gambhir SS and Willmann JK: Molecular imaging: Current status and emerging strategies. Clin Radiol 65: 500-516, 2010.
53. Condeelis J and Weissleder R: In vivo imaging in cancer. Cold Spring Harb Perspect Biol 2: a003848, 2010.
54. Walling MA, Novak JA and Shepard JRE: Quantum dots for live cell and in vivo imaging. Int J Mol Sci 10: 441-491, 2009.
55. Ruan G, Agrawal A, Marcus AI and Nie S: Imaging and tracking of tat peptide-conjugated quantum dots in living cells: New insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc 129: 14759-14766, 2007.
56. Lei Y, Tang H, Yao L, Yu R, Feng M and Zou B: Applications of mesenchymal stem cells labeled with Tat peptide conjugated quantum dots to cell tracking in mouse body. Bioconjug Chem 19: 421-427, 2008.
57. Prantner AM, Sharma V, Garbow JR and Piwnica-Worms D: Synthesis and characterization of a Gd-DOTA-D-permeation peptide for magnetic resonance relaxation enhancement of intracellular targets. Mol Imaging 2: 333-341, 2003.
58. Polyakov V, Sharma V, Dahlheimer JL, Pica CM, Luker GD and Piwnica-Worms D: Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy. Bioconjug Chem 11: 762-771, 2000.
59. Jiménez-Mancilla N, Ferro-Flores G, Santos-Cuevas C, Ocampo-García B, Luna-Gutiérrez M, Azorín-Vega E, Isaac-Olivé K, Camacho-López M and Torres-García E: Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells. J Labelled Comp Radiopharm 56: 663-671, 2013.
60. Santos-Cuevas CL, Ferro-Flores G, Rojas-Calderón EL, García-Becerra R, Ordaz-Rosado D, Arteaga de Murphy C and Pedraza-López M: 99mTc-N2S2-Tat (49-57)-bombesin internalized in nuclei of prostate and breast cancer cells: Kinetics, dosimetry and effect on cellular proliferation. Nucl Med Commun 32: 303-313, 2011.
61. Weinstain R, Savariar EN, Felsen CN and Tsien RY: In vivo targeting of hydrogen peroxide by activatable cell-penetrating peptides. J Am Chem Soc 136: 874-877, 2014.
62. Good L, Awasthi SK, Dryselius R, Larsson O and Nielsen PE: Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol 19: 360-364, 2001.
63. Deshayes S, Konate K, Aldrian G, Crombez L, Heitz F and Divita G: Structural polymorphism of non-covalent peptide-based delivery systems: Highway to cellular uptake. Biochim Biophys Acta 1798: 2304-2314, 2010.
64. Tan XX, Actor JK and Chen Y: Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: Proof of principle using mouse intraperitoneal infection. Antimicrob Agents Chemother 49: 3203-3207, 2005.
65. Tilley LD, Mellbye BL, Puckett SE, Iversen PL and Geller BL: Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: Dose-response in mice infected with Escherichia coli. J Antimicrob Chemother 59: 66-73, 2007.
66. Makarov SS: NF-kappa B in rheumatoid arthritis: A pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 3: 200-206, 2001.
67. Brown JD, Lin CY, Duan Q, Griffin G, Federation AJ, Paranal RM, Bair S, Newton G, Lichtman AH, Kung AL, et al: NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell 56: 219-231, 2014.
68. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y and Hirsch EC: Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci USA 94: 7531-7536, 1997.
69. Karin M and Greten FR: NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759, 2005.
70. May MJ, D'Acquisto F, Madge LA, Glöckner J, Pober JS and Ghosh S: Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289: 1550-1554, 2000.
71. Davé SH, Tilstra JS, Matsuoka K, Li F, Karrasch T, Uno JK, Sepulveda AR, Jobin C, Baldwin AS, Robbins PD and Plevy SE: Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J Immunol 179: 7852-7859, 2007.
72. Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, Delfín DA, DiRienzo K, Clemens PR, Robbins PD, Baldwin AS, et al: Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med 17: 508-515, 2011.
73. Hegedüs R, Manea M, Orbán E, Szabó I, Kiss E, Sipos E, Halmos G and Mező G: Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates. Eur J Med Chem 56: 155-165, 2012.
74. Pan L, Liu J, He Q, Wang L and Shi J: Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials 34: 2719-2730, 2013.
75. Kondo E, Saito K, Tashiro Y, Kamide K, Uno S, Furuya T, Mashita M, Nakajima K, Tsumuraya T, Kobayashi N, et al: Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nat Commun 3: 951, 2012.
76. Koshkaryev A, Piroyan A and Torchilin VP: Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Lett 334: 293-301, 2013.
77. Walker L, Perkins E, Kratz F and Raucher D: Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm 436: 825-832, 2012.
78. Aroui S, Mili D, Brahim S, De Waard M and Kenani A: Doxorubicin coupled to penetratin promotes apoptosis in CHO cells by a mechanism involving c-Jun NH2-terminal kinase. Biochem Biophys Res Commun 396: 908-914, 2010.
79. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH and Wender PA: Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci USA 105: 12128-12133, 2008.
80. Lindgren M, Rosenthal-Aizman K, Saar K, Eiríksdóttir E, Jiang Y, Sassian M, Ostlund P, Hällbrink M and Langel U: Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol 71: 416-425, 2006.
81. Kanasty R, Dorkin JR, Vegas A and Anderson D: Delivery materials for siRNA therapeutics. Nat Mater 12: 967-977, 2013.
82. Muratovska A and Eccles MR: Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 558: 63-68, 2004.
83. Favaro MT, de Toledo MA, Alves RF, Santos CA, Beloti LL, Janissen R, de la Torre LG, Souza AP and Azzoni AR: Development of a non-viral gene delivery vector based on the dynein light chain Rp3 and the TAT peptide. J Biotechnol 173: 10-18, 2014.
84. Wang HY, Chen JX, Sun YX, Deng JZ, Li C, Zhang XZ and Zhuo RX: Construction of cell penetrating peptide vectors with N-terminal stearylated nuclear localization signal for targeted delivery of DNA into the cell nuclei. J Control Release 155: 26-33, 2011.
85. Schott JW, Galla M, Godinho T, Baum C and Schambach A: Viral and non-viral approaches for transient delivery of mRNA and proteins. Curr Gene Ther 11: 382-398, 2011.
86. Eto Y, Yoshioka Y, Asavatanabodee R, Kida S, Maeda M, Mukai Y, Mizuguchi H, Kawasaki K, Okada N and Nakagawa S: Transduction of adenovirus vectors modified with cell-penetrating peptides. Peptides 30: 1548-1552, 2009.
87. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ and Sessa WC: Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med 9: 357-362, 2003.
88. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872, 2007.
89. Ebrahimi B: Reprogramming barriers and enhancers: Strategies to enhance the efficiency and kinetics of induced pluripotency. Cell Regen (Lond) 4: 10, 2015.
90. Gotoh S, Ito I, Nagasaki T, Yamamoto Y, Konishi S, Korogi Y, Matsumoto H, Muro S, Hirai T, Funato M, et al: Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells. Stem Cell Rep 3: 394-403, 2014.
91. Kamao H, Mandai M, Okamoto S, Sakai N, Suga A, Sugita S, Kiryu J and Takahashi M: Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep 2: 205-218, 2014.
92. Waehler R, Russell SJ and Curiel DT: Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587, 2007.
93. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P, Gertsenstein M, et al: piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458: 766-770, 2009.